Trial Profile
A Randomized, Double-Blind, Parallel, Phase I Pharmacokinetic Trial Comparing The Potential Biosimilar ALT02(Trastuzumab) With Herceptin in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Pharmacokinetics
- Sponsors Alteogen
- 10 Aug 2017 New trial record